Transforming Cutting-Edge Science
into Breakthrough Therapies
We develop first-in-class and best-in-class medicines for hard-to-treat cancer and Alzheimer’s disease
Leveraging innate and adaptive immune checkpoints—CTLA-4, PD-1/VEGF, CD24, and Siglec—we have the potential to target cancer cells and boost immune response like never before.
Our scientific approach
From pioneering research to developing next-generation therapeutics, we are poised to make cancer therapies safer, more effective, and more durable.
CTLA-4 Program
A new and enduring generation of CTLA-4 antibody therapy is here. Discover how gotistobart, currently partnering with BioNTech, is poised to change the treatment of patients with immunotherapy-resistant non–small cell lung cancer and other advanced tumors.
Siglec Programs
Siglecs play a key role in modulating immune responses through cell–cell interactions. We’re targeting Siglec signaling to unleash anti-tumor immunity for oncology and to restore microglial function for neurodegenerative diseases.
CD24 Platform
CD24 is overexpressed in approximately 70% of human cancers, making it a promising therapeutic target. However, its expression on normal tissues posed a major challenge for CD24-directed therapies. We have developed a tumor-selective anti-CD24 antibody designed to overcome this major hurdle.
Pipeline
Fighting cancer and Alzheimer’s disease demands an arsenal of therapeutic approaches. That’s why we’re engineering medicines that leverage a diverse array of modalities, including monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs). Discover what we have in our pipeline.
Join our team
Interested in joining a smart and collaborative team that’s changing how medicine treats the toughest cancers? Explore our job openings and get in touch.
Global Capabilities
With headquarters in Maryland, United States, we operate as a lean and efficient team with a global footprint. The combination of innovative science, differentiated drug candidates, and global execution capabilities positions us to deliver transformative medicines to patients worldwide.
See our global capabilities
